

FOR IMMEDIATE RELEASE

Vystar Corporation

Betty Orsey

(678) 427-1766

borsej@pointbagency.com

Vystar Corporation

Colleen Golden

(404) 888-1700 x111

cgolden@pointbagency.com

**ATLANTA HEALTHCARE ENTREPRENEUR
JOINS VYSTAR BOARD OF DIRECTORS**

Atlanta, GA, May 7, 2008 — Joseph P. Allegra, MD., founder/owner of Atlanta area companies, Diamond II Investments, Oncology Molecular Imaging and Pediatric Urgent Care, has joined Vystar Corporation's board of directors.

Atlanta-based Vystar is the developer of the revolutionary new Vytex™ natural rubber latex (NRL) produced through a proprietary process that chemically modifies NRL to reduce the allergenic proteins commonly found in latex.

Announcing Dr. Allegra's appointment, Vystar Chief Executive Officer William Doyle said, "Dr. Allegra's broad-based medical and business experience will be a tremendous asset to Vystar as we move into full-scale production of Vytex™ natural rubber latex with Revertex Malaysia. Dr. Allegra believes in our product's ability to meet the demand for NRL that removes virtually all the antigenic proteins and also understands the health care concerns driving this demand."

Dr. Allegra's 30+-year-career in the health care industry includes numerous professorships and chairmanships as a practicing oncologist as well as board certifications, published works, industry awards and medical licensing in five states. He holds an undergraduate degree in Chemistry from Temple University and obtained his doctor of medicine from Milton S. Hershey Medical Center at Pennsylvania State University. He is also the owner of Cyberlogistics, Inc. and a partner with the Seraph Group.

Dr. Allegra joins the Vystar board just as the company has finalized a contract with Revertex Malaysia for the manufacture of Vytex NRL. Vystar is currently shipping Vytex NRL for manufacturers' evaluation trials across a broad swath of industries: healthcare (surgical and exam gloves, probe covers, breather bags, etc.); condoms, adhesives and foam. With more than 500 product samples tested, Doyle said he feels there is every reason to believe that manufacturers will have products made with Vytex NRL in production late 2008 or early 2009.

Vytex NRL has been in development since 2002. The current manufacturer evaluation trials enable manufacturers to work with Vytex NRL within their own production environment to assess performance in their products and applications. Earlier trials



at select condom, glove and other medical device manufacturers demonstrated that Vytex NRL integrates seamlessly into most manufacturing processes in place of either NRL or synthetic substitutes with few to no changes to the overall process.

About Vystar Corporation: Vystar Corporation, incorporated in 2003, is a privately funded corporation located in the Atlanta area. It is included in the portfolio of Universal Capital Management, Inc. (OTC BB:UCMT.OB), a business development company that provides management and strategic growth resources to emerging growth companies. The company's operations have been focused substantially on early-stage research, development, testing and commercialization of the Vytex NRL process. Vystar, named a 2007 Top 10 Innovative Technology Company in Georgia by the Technology Association of Georgia (TAG), holds two U.S. patents for the Vytex™ NRL technology, with additional filings pending. For more information, please visit www.vytex.com.

Forward-looking Statements: Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words, such as Vystar Corporation "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe Vystar's future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Vystar as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Vystar believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and Vystar does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

###

